MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis
نویسندگان
چکیده
منابع مشابه
Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study)
BACKGROUND Risk models of chemotherapy-induced (CIN) and febrile neutropenia (FN) have to date focused on determinants measured at the start of chemotherapy. We extended this static approach with a dynamic approach of CIN/FN risk modeling at the start of each cycle. DESIGN We applied predictive modeling using multivariate logistic regression to identify determinants of CIN/FN episodes and rel...
متن کاملBiosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia
Background We studied the comparative effectiveness of biosimilar filgrastim vs original filgrastim in patients with chemotherapy-induced neutropenia. Patients and methods This multicenter, observational study was conducted at 14 centers. The study included 337 patients experiencing neutropenia under chemotherapy. Patients were given either filgrastim 30 MIU or 48 MIU (Neupogen®) or biosimila...
متن کاملPrevention and treatment of chemotherapy-induced neutropenia with the biosimilar filgrastim: a non-interventional observational study of clinical practice patterns.
BACKGROUND Biosimilars are similar but non-identical versions of existing biological drugs. The HEXAFIL study was an observational study that assessed the clinical usage, safety and efficacy of the biosimilar filgrastim in routine clinical practice in Germany. PATIENTS AND METHODS A total of 1,337 cancer patients received the biosimilar filgrastim for primary prophylaxis (PP), secondary proph...
متن کامل1501pcomparison of the Efficacy of Filgrastim (neupogen®) and Biosimilar Filgrastim (leucostim®) in Patients with Chemotherapy-induced Neutropenia: a Nationwide Observational Study.
A. Sevinc1, M. Ozkan2, A. Ozet3, F. Dane4, B. Oksuzoglu5, A. Isikdogan6, F. Ozdemir7, D. Uncu8, M. Gumus9, T. Evrensel10, A. Yaren11, O. Kara12, S.B. TekIṅ13 Medical Oncology Department, Gaziantep University Onkoloji Hastanesi, Gaziantep, TURKEY Medical Oncology, Erciyes University Medical Faculty M. Kemal Dedeman, Oncology Hospital, Kayseri, TURKEY Medical Oncology, Gazi University Faculty of ...
متن کاملCompatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study
INTRODUCTION Febrile neutropenia (FN) is a serious and frequent complication of cytotoxic chemotherapy. Biosimilar filgrastim (Nivestim™, Hospira Inc, A Pfizer Company, Lake Forest, IL, USA) is a granulocyte-colony stimulating factor licensed for the treatment of neutropenia and FN induced by myelosuppressive chemotherapy. The primary goal of this VENICE study (ClinicalTrials.gov identifier, NC...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Haematology
سال: 2017
ISSN: 0902-4441
DOI: 10.1111/ejh.13002